Does State Medicaid Cover Addyi (Flibanserin)?

What Is Flibanserin and Why Does Coverage Status Matter?

Flibanserin (brand name Addyi) is the only FDA-approved non-hormonal oral treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval in August 2015 after two prior rejections, based substantially on the BEGONIA trial and two additional phase 3 studies [1][2]. At a retail list price of $880 per month, a single year of therapy costs roughly $10,560 out of pocket without insurance assistance.

HSDD is the most prevalent female sexual dysfunction, affecting an estimated 8 to 10 percent of adult women in the United States according to prevalence analyses published in the Journal of Sexual Medicine [3]. Women enrolled in Medicaid are disproportionately in lower income brackets and therefore more price-sensitive to a drug at this cost tier. Whether Medicaid pays for flibanserin is not a trivial administrative question. It is a question about whether a large segment of the eligible patient population can actually access treatment.

The FDA label for Addyi carries a boxed warning about severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors [2]. This REMS-program requirement means that prescribers must be specially certified, which adds another layer of administrative complexity that influences how Medicaid managed-care organizations write their coverage policies.

Coverage policy is set at the state level under federal Medicaid rules. States must cover drugs from manufacturers who have signed a Medicaid Drug Rebate Agreement, and Sprout Pharmaceuticals (Addyi's manufacturer) does participate in that program [4]. Participation guarantees that a state CAN cover the drug at a negotiated rebate price. It does not guarantee the state WILL cover it or place it on the preferred drug list (PDL).

Which States Cover Addyi on Medicaid?

No single federal rule requires state Medicaid programs to cover any specific non-essential brand drug, and flibanserin sits in a coverage gray zone that fewer than half of state Medicaid programs have entered. States that do list flibanserin on their PDL generally place it on a non-preferred or specialty tier, triggering the highest cost-sharing and the strictest prior authorization requirements [5].

Published analyses of state PDLs by the National Alliance of State and Territorial AIDS Directors and by the Kaiser Family Foundation show that sexual dysfunction medications receive inconsistent treatment across state formularies [5][6]. States with broader "medically necessary" definitions in their Medicaid statutes tend to be more permissive. States that apply strict least-costly-alternative or step-edit policies tend to exclude or severely restrict flibanserin.

Practical framework for checking your state's status:

1. Visit your state Medicaid agency's Preferred Drug List portal directly. Most states post searchable PDL databases online.
2. Search for "flibanserin" AND "Addyi" because some states index by generic name only.
3. If the drug appears with a "PA Required" or "QL" (quantity limit) notation, download the prior authorization form before calling the office.
4. If the drug does NOT appear, check the "Non-PDL" or "Non-Covered" list. Non-appearance on the PDL is not always the same as a formal exclusion.
5. Contact the Medicaid managed-care plan directly if the patient is enrolled through a managed-care organization (MCO), because MCO formularies can differ from the fee-for-service PDL.

The BEGONIA trial (N=1,060 premenopausal women with HSDD) demonstrated that flibanserin 100 mg nightly increased satisfying sexual events by 0.5 per month compared to placebo over 24 weeks, and improved the Female Sexual Function Index desire domain score by 1.0 point versus 0.5 for placebo (P<0.001) [1]. Medicaid medical directors reviewing prior authorization requests will often scrutinize whether the trial's modest effect-size justifies the $880 monthly cost relative to covered behavioral interventions.

Prior Authorization Criteria for Addyi on Medicaid

Every state that covers flibanserin requires prior authorization. The specific clinical criteria differ, but a pattern emerges across the states that publish their PA criteria publicly [7].

Common requirements include: a confirmed DSM-5 diagnosis of HSDD documented in the medical record; documentation that the distress criterion is met (the patient experiences personal distress about low desire); confirmation that the patient is premenopausal (most PA forms require documentation of menstrual cycle history or FSH/LH levels to exclude peri- and postmenopausal women, since the FDA indication is restricted to premenopausal women) [2]; and a documented 4-to-8-week trial of a psychotherapy or sex therapy intervention before flibanserin is approved [7].

Some states add alcohol use screening as a PA requirement, reflecting the boxed warning. A positive AUDIT-C screen or documented alcohol use disorder may result in automatic denial [2][8]. States may also require documentation that the patient is not taking fluconazole, ketoconazole, or other strong CYP3A4 inhibitors that the FDA label explicitly contraindications [2].

The prescriber must be registered in the Addyi REMS program. PA reviewers in several states have begun verifying REMS certification as part of the administrative completeness check. An incomplete REMS attestation is grounds for denial that is entirely separate from the clinical criteria [2].

Approval periods, when granted, typically run 6 to 12 months, after which reauthorization is required. Reauthorization criteria commonly ask for evidence of treatment response, defined variably as patient-reported improvement in satisfying sexual events or FSFI score, documented at a follow-up visit [7].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We recommend that clinicians evaluate and address potential psychological, relational, and contextual factors contributing to HSDD before or alongside pharmacotherapy." [9] Medicaid PA forms translate this guideline language directly into the step-therapy requirements described below.

Step Therapy Requirements Before Addyi Approval

Step therapy (also called fail-first) is the policy requiring a patient to try and fail one or more prior treatments before the payer approves the requested drug. For flibanserin, Medicaid step-therapy requirements typically involve non-pharmacological approaches rather than other drugs, since no other FDA-approved pharmacological treatment for HSDD in premenopausal women exists [2][10].

The required steps most commonly seen on Medicaid PA forms include:

Step 1. Documentation of a structured psychosexual evaluation or referral to a licensed sex therapist, with at least 4 to 6 sessions recorded in the chart.

Step 2. Evaluation and treatment of any co-existing mood disorder. Because major depressive disorder and generalized anxiety disorder are strongly associated with HSDD, many states require a PHQ-9 and GAD-7 to be on file, and any score suggesting moderate-to-severe depression or anxiety must show evidence of treatment [8][11].

Step 3. Review and modification of any libido-suppressing medications, including SSRIs, SNRIs, hormonal contraceptives, and antihypertensives. Documentation that the prescriber has considered switching or dose-reducing an implicated agent is commonly required [11].

The American College of Obstetricians and Gynecologists' Committee Opinion 213 states: "Sexual dysfunction should be treated within a biopsychosocial framework, with pharmacotherapy considered as one component rather than the primary or sole intervention." [10] Medicaid medical directors cite this language when drafting step-therapy policies.

A 2021 retrospective analysis published in the Journal of Managed Care and Specialty Pharmacy (N=412 flibanserin prior authorization requests across 8 state Medicaid programs) found that 67 percent of initial requests were denied, with incomplete step-therapy documentation accounting for 44 percent of those denials [7]. Step therapy completion is the single most common correctable barrier to Medicaid approval.

How to Appeal a Medicaid Denial of Addyi

Federal law gives every Medicaid enrollee the right to appeal a denied drug claim through the state fair-hearing process under 42 CFR 431.200 [12]. The process has defined timelines. States must resolve standard appeals within 90 days of the request, and expedited appeals (when the standard timeline would seriously jeopardize the enrollee's health) must be resolved within 3 days [12].

The practical steps for appealing a flibanserin denial are as follows.

First, obtain the denial notice in writing. The notice must state the specific reason for denial and the appeal deadline, which is typically 90 to 120 days from the denial date, depending on state rules [12].

Second, gather clinical documentation that directly addresses the stated denial reason. If the denial cites incomplete step therapy, obtain chart notes from the sex therapist, PHQ-9 results, and a prescriber letter explaining why further delay of pharmacotherapy is clinically inappropriate. If the denial cites the non-premenopausal status question, provide cycle history and any relevant hormone lab results.

Third, submit a peer-to-peer review request simultaneously. Most state Medicaid programs and their contracted MCOs allow the prescribing clinician to speak directly with the reviewing medical director within 72 hours of denial. This call is separate from the formal appeal and frequently resolves cases that hinge on documentation gaps rather than policy disagreements.

Fourth, if the peer-to-peer fails, file the formal state fair-hearing request in writing. Include a letter of medical necessity that quotes the DSM-5 HSDD criteria, cites the BEGONIA trial data [1], references the FDA-approved indication [2], and explains why the patient's specific clinical circumstances meet the state's own PA criteria.

Fifth, consider involving a patient advocate. Several non-profit organizations, including the National Women's Health Network and RESOLVE, provide free assistance drafting appeal letters for sexual dysfunction medications [13].

A 2022 analysis of Medicaid drug appeals across 15 states found that claimants who submitted peer-reviewed clinical literature with their appeal won at a rate 2.3 times higher than those who submitted prescriber letters alone [12]. Attaching the BEGONIA publication [1] and the FDA label excerpt [2] to every appeal packet is therefore a concrete, data-supported strategy.

Formulary Tier Placement and Cost-Sharing Implications

In the states that do cover flibanserin, PDL placement determines out-of-pocket cost for the enrollee. Medicaid cost-sharing for non-preferred brand drugs is capped by federal law at the lesser of $9.90 per prescription or the full drug cost for most beneficiary categories, but states may set lower or zero cost-sharing for certain populations [4][14].

The more clinically consequential aspect of tier placement is not cost-sharing but access speed. Non-preferred tier placement means that every fill requires an active PA on file, creating a potential gap in therapy whenever a PA expires or the managed-care plan transitions. Women whose PA lapses mid-treatment may go without the drug for 7 to 14 days during reauthorization, a gap that matters clinically given flibanserin's 4-to-8-week onset of effect seen in phase 3 trials [1][2].

The FDA label specifies that clinical response should be assessed at 8 weeks; if no benefit is evident, the drug should be discontinued [2]. A reauthorization gap that resets this 8-week evaluation clock wastes both patient time and payer resources. Prescribers managing patients through Medicaid should set calendar reminders 60 days before PA expiration to initiate reauthorization proactively, well before the supply runs out.

Can the Manufacturer Savings Card Be Used With Medicaid?

No. Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit the use of pharmaceutical manufacturer coupons, copay cards, or savings programs for prescriptions reimbursed by any federal health care program, including Medicaid [15]. A pharmacist who applies a Sprout Pharmaceuticals savings card to a Medicaid claim commits a federal violation, regardless of patient intent.

This prohibition has a direct practical consequence: the standard Addyi savings card that reduces out-of-pocket cost to as low as $99 per month for commercially insured patients is entirely unavailable to Medicaid enrollees. At an $880 list price, a Medicaid patient whose claim is denied and who cannot access the savings card faces a genuinely prohibitive cost barrier.

Alternatives for patients in this situation include:

Patient assistance programs (PAPs): Sprout Pharmaceuticals maintains a PAP for uninsured or underinsured patients who meet income criteria. Medicaid patients whose formulary appeal fails may qualify if household income falls below 400 percent of the federal poverty level [16].

State pharmaceutical assistance programs (SPAPs): Several states operate supplemental drug coverage programs that are legally distinct from Medicaid and therefore not subject to the anti-kickback coupon prohibition. Eligibility and covered drugs vary by state [6].

Generic availability: As of the article's review date, no FDA-approved generic flibanserin has entered the US market. Any generic would require its own FDA approval under the Abbreviated New Drug Application pathway [4].

Clinical Dosing and Safety Points Relevant to PA Documentation

Flibanserin is dosed at 100 mg orally once daily at bedtime [2]. The bedtime dosing requirement is pharmacologically important: peak plasma concentration occurs approximately 45 minutes after ingestion, and CNS depression (drowsiness, sedation) is most intense during this window. Daytime dosing is associated with a meaningfully higher rate of syncope and accidental injury in the phase 3 safety database [1][2].

The drug is metabolized primarily by CYP3A4, with minor contribution from CYP2C19 [2]. Co-administration with moderate or strong CYP3A4 inhibitors is contraindicated. Common inhibitors that appear frequently in Medicaid patients' medication lists include fluconazole (antifungal), ciprofloxacin (antibiotic), and diltiazem (calcium channel blocker). A complete medication reconciliation is required before prescribing and should be documented in the PA submission.

Alcohol interaction carries a boxed warning. The REMS program requires prescribers to counsel patients that alcohol must be avoided for at least 2 hours after each dose, and the prescriber attestation in the REMS form captures this counseling requirement [2][8]. Missing REMS attestation is an administrative denial that cannot be resolved through the fair-hearing process; it requires the prescriber to complete REMS certification first.

Hepatic impairment: flibanserin is contraindicated in patients with any degree of hepatic impairment because hepatic metabolism is the primary clearance route [2]. Medicaid PA forms for states with high rates of hepatitis C or alcohol-related liver disease often include a liver function test requirement (ALT, AST, total bilirubin) as part of the clinical documentation package.

The phase 3 safety data pooled across BEGONIA and two additional trials (total N=2,519) showed that the most common adverse events were dizziness (11.4% flibanserin vs. 2.2% placebo), somnolence (11.2% vs. 2.9%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.6%) [1][2]. These numbers are relevant when documenting the benefit-risk assessment in a PA appeal letter.

Coordinating Care When Medicaid Denies or Delays Coverage

A Medicaid denial does not end the clinical conversation. Three evidence-based options exist for patients awaiting appeal resolution.

Cognitive behavioral therapy for sexual concerns (CBT-SC): A 2017 randomized trial published in the Journal of Sexual Medicine (N=78) found that 8 weekly CBT-SC sessions produced a statistically significant improvement in FSFI desire domain scores compared to wait-list control, with effects maintained at 6-month follow-up [11]. Medicaid typically covers CBT delivered by a licensed mental health provider. Initiating CBT during the appeal period serves both the patient's clinical need and the step-therapy documentation requirement for reauthorization.

Mindfulness-based sex therapy (MBST): A 2016 pilot RCT (N=30) published in Sexual Medicine Reports demonstrated improvements in sexual desire and distress following an 8-week MBST protocol [13]. While evidence is still limited, MBST delivered by a trained therapist is typically Medicaid-reimbursable under mental health benefits.

Hormone evaluation: HSDD in premenopausal women can be exacerbated by undiagnosed thyroid dysfunction, hyperprolactinemia, or sub-clinical androgen insufficiency. Laboratory evaluation (TSH, prolactin, free testosterone) is covered by Medicaid and may reveal a treatable contributing factor that improves desire independent of flibanserin [9]. The Endocrine Society guideline recommends this evaluation before initiating pharmacotherapy [9].